Oncotarget

Meta-Analysis:

Clinicopathological significance of CHFR promoter methylation in gastric cancer: a meta-analysis

Yong Ding, Hai-Feng Lian and Yaowu Du _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:10083-10090. https://doi.org/10.18632/oncotarget.23394

Metrics: PDF 1842 views  |   HTML 2576 views  |   ?  


Abstract

Yong Ding1, Hai-Feng Lian2 and Yaowu Du3

1School of Basic Medical Science, Henan University, Kaifeng, 475004, China

2Department of Gastroenterology, Affiliated Hospital of Binzhou Medical College, Binzhou, 256600, China

3Laboratory for Nanomedicine, School of Basic Medical Science, Henan University, Kaifeng, 475004, China

Correspondence to:

Yaowu Du, email: [email protected]

Keywords: CHFR; methylation; gastric cancer; biomarker; drug target

Received: August 21, 2017     Accepted: November 16, 2017     Published: December 16, 2017

ABSTRACT

The mitotic checkpoint gene (CHFR) (Checkpoint with Forkhead-associated and Ring finger domains is a G2 phase/mitosis checkpoint and tumor-suppressor gene. Recent studies have reported the relationship of CHFR promoter methylation with clinicopathological significance of gastric cancer. However, the results remain unclear due to small size of sample. We pooled 15 studies including 827 gastric cancer patients and conducted a meta-analysis to investigate the clinicopathological significance of CHFR promoter methylation in gastric cancer. Our data revealed that the frequency of CHFR promoter methylation was higher in gastric cancer than in normal gastric tissue, Odd Ratio (OR) was 10.12 with 95% CI 5.17–19.79, p < 0.00001. Additionally, the rate of CHFR promoter methylation was significantly increased in high grade of gastric cancer compared to low grade, OR was 1.64 with 95% CI 1.00–2.68, p = 0.05. CHFR methylation was significantly associated with the positive lymph node metastasis, OR was 1.56 with 95% CI 1.05–2.32, p = 0.03. We concluded that CHFR could serve as a biomarker for diagnosis of gastric cancer, and a drug target for development of gene therapy in gastric cancer. CHFR promoter methylation is associated with tumor poor differentiation and lymph node metastasis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23394